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ABSTRACT
Background. Estimated albumin excretion rate (eAER) pro-
vides a better estimate of 24-h albuminuria than albumin:creati-
nine ratio (ACR). However, whether eAER is superior to ACR
in predicting end-stage renal disease (ESRD), vascular events
(VEs) or death is uncertain.
Methods. The prognostic utility of ACR and eAER (estimated
from ACR, sex, age and race) to predict mortality, ESRD and
VEs was compared using Cox proportional hazards regression
among 5552 participants with chronic kidney disease in the
Study of Heart and Renal Protection, who were not on dialysis
at baseline.
Results. During a median follow-up of 4.8 years, 1959 partici-
pants developed ESRD, 1204 had a VE and 1130 died (641 from
a non-vascular, 369 from a vascular and 120 from an unknown
cause). After adjustment for age, sex and eGFR, both ACR and
eAER were strongly and similarly associated with ESRD risk.
The average relative risk (RR) per 10-fold higher level was 2.70
(95% conﬁdence interval 2.45–2.98) for ACR and 2.67 (2.43–
2.94) for eAER. Neither ACR nor eAER provided any additional
prognostic information for ESRD risk over and above the other.
For VEs, there were modest positive associations between both
ACR and eAER and risk [adjusted RR per 10-fold higher level
1.37 (1.22–1.53) for ACR and 1.36 (1.22–1.52) for eAER].
Again, neither measure added prognostic information over and
above the other. Similar results were observed when ACR and
eAER were related to vascular mortality [RR per 10-fold higher
level: 1.64 (1.33–2.03) and 1.62 (1.32–2.00), respectively] or to
non-vascular mortality [1.53 (1.31–1.79) and 1.50 (1.29–1.76),
respectively].
Conclusions. In this study, eAER did not improve risk predic-
tion of ESRD, VEs or mortality.
VC The Author 2017. Published by Oxford University Press
on behalf of ERA-EDTA. This is an Open Access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and
reproduction in any medium, provided the original work is properly cited.
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INTRODUCTION
People with chronic kidney disease (CKD) face two major haz-
ards: premature morbidity and mortality (in particular from
cardiovascular disease) and progression to end-stage renal dis-
ease (ESRD) [1]. Measures of kidney function [e.g. estimated
glomerular filtration rate (eGFR)] and markers of kidney dam-
age (e.g. albuminuria) are associated with the risk of ESRD, vas-
cular disease and death, both in the general population [2] and
among those with CKD [3], although both are more strongly
associated with ESRD than with vascular events (VEs) and
death [4, 5].
Albuminuria is traditionally measured by timed urine collec-
tion but current guidelines recommend the measurement of
albumin: creatinine ratio (ACR) in a spot urine sample, because
ACR provides a reasonably accurate indication of albuminuria
and is more convenient for patients [6, 7]. The ACR uses urine
creatinine concentration as the denominator to account for
urine concentration, but, since urine creatinine concentration is
also affected by muscle mass, ACR may not reflect albuminuria
accurately in some individuals [8].
Recently, equations have been developed to estimate the
urine creatinine excretion rate (eCER) from age, sex and race
(and weight in some cases) so that the ACR can be adjusted for
factors related to muscle mass by calculating the estimated albu-
min excretion rate (eAER). Studies have shown that eAER esti-
mates 24-h albumin excretion more accurately than ACR alone
[9–11]. However, whether these measures provide additional
prognostic information (i.e. improved ability to predict the risk
of a future outcome) over ACR for ESRD, VEs or mortality is
not known. Using data from 5552 participants with CKD in the
Study of Heart of Renal Protection (SHARP) who were not on
dialysis at study entry [12], we assessed whether eAER provides
superior prognostic information to ACR alone.
MATERIALS AND METHODS
The SHARP trial investigated the efficacy of lowering low-den-
sity lipoprotein cholesterol (LDL-C) with simvastatin/ezetimibe
in 9270 participants with CKD (of whom 6245 were not on dial-
ysis at randomization) [12]. The trial methods have been pub-
lished in detail elsewhere and are summarized below [12, 13].
Ethics committee approval was obtained from all sites prior to
enrolment and the study was conducted in accordance with the
Declaration of Helsinki. SHARP was registered at
ClinicalTrials.gov (NCT00125593) on 29 July 2005.
Study participants
Individuals aged 40 years or over were eligible to participate
in SHARP if they had CKD with more than one previous meas-
urement of serum or plasma creatinine of at least 1.7mg/dL in
men or 1.5mg/dL in women. Participants with prior myocardial
infarction or coronary revascularization were excluded. All
participants provided informed consent prior to enrolment in
the trial. Among the 6245 individuals not on dialysis at baseline,
no baseline urine ACR was available for 673 participants and a
further 20 had missing baseline central eGFR, leaving 5552 par-
ticipants for analysis in this report (Figure 1).
Baseline assessment
Self-reported history of prior vascular disease, diabetes,
smoking status, race, co-medication and cause of kidney dis-
ease were recorded by trained study staff. The recorded cause
of kidney disease was based on the clinical diagnosis of the
managing physician and subsequently categorized into four
groups: glomerulonephritis, diabetic nephropathy, cystic kid-
ney disease and other causes (including unknown) [14].
Blood pressure, height and weight were measured by the
study staff.
Laboratory methods
Samples of non-fasting blood and urine (whenever in the
day the visit occurred) were collected from all participants.
Blood samples were cooled, centrifuged and separated, before
being stored locally at 40 C. Samples were then shipped on
dry ice to the central laboratory in Oxford where assays of
plasma creatinine and urine ACR were conducted. Creatinine
and albumin were measured using a Synchron LX20 or
DXC800 analyser (Beckman Coulter, Brea, CA, USA).
Creatinine was assayed using a kinetic alkaline picrate method,
calibrated using material traceable to National Institute of
Standards and Technology Standard Reference Material 914a,
with a mean expanded uncertainty of 13.4% (7.3% excluding
biological variation). eGFR was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) for-
mula [15]. eAER was calculated by:
FIGURE 1: Eligibly criteria and participant selection. ACR, albumin
creatinine ratio; eGFR, estimated glomerular ﬁltration rate; SHARP,
Study of Heart and Renal Protection.||
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eAER ðmg=dayÞ ¼ ACR ðmg=gÞ  eCER ðg=dayÞ:
The eCER was calculated using the formula developed from the
Modification of Diet in Renal Disease (MDRD) study as this did
not require knowledge of the individual’s weight and so is more
likely to be used in clinical practice (eAEREllam) [9]. Sensitivity
analyses were conducted using other eCER formulae (eAERIx
and eAERWalser) [10, 11], restricted to the 5522 participants
with information on weight at baseline. The eCER formulae are
provided in the Supplementary data.
Follow-up
Participants were to be seen at 2 and 6 months after random-
ization, and then every 6 months until final follow-up.
Information on all serious adverse events was sought at each
visit and further documentation collected on events of interest
(including initiation of renal replacement therapy and possible
VEs) by study staff. This information was sent to the interna-
tional coordinating centre, in Oxford, for central adjudication.
A non-fasting blood and urine sample for central laboratory
analysis was requested from all participants known to be alive at
2.5 years after randomization.
The main outcomes of interest for these analyses were
ESRD, VEs, vascular mortality and non-vascular mortality. The
outcome of VEs used in this analysis includes a broader range
of events than the pre-specified outcome used for the main trial
results [12]. For this analysis, VEs include any cardiovascular
death, non-fatal myocardial infarction, hospitalization with
angina, any stroke, arterial revascularization, heart failure,
arrhythmia or valvular heart disease (see Supplementary data).
ESRD was defined as initiation of maintenance dialysis or renal
transplantation.
Statistical analysis
Cox proportional hazards regression was used to compare
the relevance of ACR and eAER to the risk of ESRD, VEs and
mortality over the period studied. The proportional hazard
assumption was tested through examination of the time-
dependency of the Schoenfeld partial residuals. The analyses
were adjusted for baseline age, sex and eGFR. Analyses of VEs
and mortality were also adjusted for other established cardio-
vascular risk factors [ethnicity, country, systolic and diastolic
blood pressure, LDL-C, high-density lipoprotein cholesterol
(HDL-C), smoking status, prior diabetes and prior vascular dis-
ease]. There were complete data on all these variables with the
exception of systolic and diastolic blood pressure, LDL-C and
HDL-C, for which 17 (0.3%) participants were missing at least
one measurement. Median values were imputed for these
participants.
The analyses relate risk to the estimated ‘usual’ ACR or
eAER to correct for the regression dilution bias that would be
introduced if only the baseline values were used [16]. In the fig-
ures, relative risks (RRs: approximated by the hazard ratio esti-
mates from the Cox models) for each fifth of ‘usual’
albuminuria measure, including that for the reference group,
are accompanied by a confidence interval (CI) derived from the
variance of the log risk in that group. These group-specific CIs
can be thought of as reflecting the amount of data only in that
one group, thereby allowing appropriate statistical comparisons
to be made between any two groups [17]. For ESRD, the top
fifth is further divided into two equally sized groups, giving six
comparison groups. The association between each measure of
albuminuria with the outcomes of interest is summarized as the
RR per 10-fold increase in albuminuria marker, as this allows
comparison with other studies [18] and roughly equates to an
increase in albuminuria stage [6]. The magnitude of improve-
ment in risk prediction (over and above other baseline charac-
teristics in the model) was estimated by the difference in twice
the log-likelihood statistic between the two “nested” models
[which, under the null hypothesis of no improvement, gives a
chi-squared (v2) statistic with 1 degree of freedom]. This pro-
vides not only a test for improvement in fit, but also a quantita-
tive measure of the extent to which the added term improves
risk prediction [19] and is the uniformly most powerful test of
the incremental value of a biomarker [20]. A statistically signifi-
cant improvement is indicated by a change in v2 of at least 3.84
(for 1 degree of freedom). As a sensitivity analysis, analyses for
ESRD were repeated using Fine and Gray regression, which
yields sub-distribution hazard ratios [21], to account for the
competing risk of death before ESRD.
RESULTS
Average baseline characteristics in five groups defined by the
quintiles of baseline urine ACR are shown in Table 1.
Compared with participants with lower urine ACR, individuals
with higher urine ACR were younger, had lower eGFR and
higher blood pressure at baseline and were more likely to have a
diabetic nephropathy or glomerulonephritis recorded as the
cause of their renal disease (Table 1). The correlation between
ACR or eAER measured at baseline and a repeat measurement
(collected around 2.5 years later) was 0.75.
Measures of albuminuria and the risk of ESRD
After a median follow-up of 4.8 years among survivors, 1959
participants had reached ESRD. Both measures of albuminuria
displayed strong associations with the risk of ESRD after adjust-
ment for age, sex and eGFR (Figure 2). For both measures curvi-
linear relationships with ESRD were seen when plotted on a log-
log scale, with stronger relationships observed among those with
more albuminuria (Figure 2). The average RR throughout the
range of values studied was nearly identical for the two measures:
RR per 10-fold higher ACR 2.70 (95% CI 2.45–2.98); and per 10-
fold higher eAER 2.67 (95% CI 2.43–2.94) (Table 2). Neither
ACR nor eAER provided any additional prognostic information
for ESRD risk over and above each other [improvement in risk
prediction for eAER over and above ACR v1
2
¼0.3); for ACR over
and above eAER (v21¼0.0); Supplementary Table S1].
The predictive power of ACR and eAER for ESRD was also
similar in various subgroups; in men and women; among White
and Asian participants; among those with an eGFR 30 mL/
min/1.73 m2 and eGFR<30 mL/min/1.73 m2 at baseline; and
when the population was separated into groups by age, weight or
blood pressure (Supplementary Table S2). The prognostic utility
of eAER was tested separately in the four groups of cause of
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|kidney disease (glomerulonephritis, diabetic nephropathy, cystic
kidney disease and other causes; Supplementary Table S2). In
each category of renal disease, a model including either ACR or
eAER, along with age, sex and eGFR, was just as informative as
one using both measures (v2 with either ACR or eAER was 98–
99% of the v2 for both) although in those with cystic kidney dis-
ease neither measure of albuminuria was particularly predictive
(v2¼4.6 for the model including ACR and eAER).
In a model without adjustment for age, sex or eGFR, eAER
did not add any additional prognostic information for ESRD
risk over and above ACR (v21 ¼ 3.8), but ACR did add prognos-
tic information over and above eAER (v21 ¼ 38.3)
(Supplementary Table S1). The overall results were similar
when eAER was calculated using formulae that include weight
as well as age, sex and race (Supplementary Table S1) [10, 11].
Additionally, neither ACR nor eAER provided any additional
Table 1. Baseline demographic characteristics and physical/laboratory measurements among 5552 patients not on dialysis at randomization, by ACR group
deﬁned by the quintiles of the distribution
ACR (mg/g) P-value for
differences
between
groups
<30
n ¼ 1109
30 to <118
n ¼ 1109
118 to <347
n ¼ 1120
347 to <1012
n ¼ 1102
1012
n ¼ 1112
Age at randomization (years) 66 (12) 64 (12) 62 (11) 61 (12) 60 (12) <0.0001
Men 693 (62%) 688 (62%) 693 (62%) 712 (65%) 678 (61%) 0.48
Race
White 909 (82%) 872 (79%) 788 (70%) 731 (66%) 625 (56%) <0.0001
Black 18 (2%) 21 (2%) 16 (1%) 18 (2%) 17 (2%) 0.93
Asian 164 (15%) 195 (18%) 298 (27%) 319 (29%) 450 (40%) <0.0001
Other/not speciﬁed 18 (2%) 21 (2%) 18 (2%) 34 (3%) 20 (2%) 0.07
Prior vascular disease 153 (14%) 179 (16%) 134 (12%) 141 (13%) 201 (18%) 0.0002
Diabetes 197 (18%) 176 (16%) 233 (21%) 249 (23%) 407 (37%) <0.0001
Current smoker 89 (8%) 125 (11%) 139 (12%) 155 (14%) 181 (16%) <0.0001
Systolic blood pressure (mmHg) 134 (20) 136 (19) 138 (20) 143 (20) 148 (22) <0.0001
Diastolic blood pressure (mmHg) 77 (12) 79 (11) 79 (12) 82 (12) 83 (13) <0.0001
Body mass index (kg/m2) 27.9 (5.3) 27.3 (5.1) 27.0 (5.2) 27.0 (5.3) 27.1 (5.7) 0.0003
Renal diagnosis
Glomerulonephritis 92 (8%) 130 (12%) 211 (19%) 278 (25%) 262 (24%) <0.0001
Diabetic nephropathy 91 (8%) 86 (8%) 135 (12%) 161 (15%) 319 (29%) <0.0001
Cystic kidney disease 128 (12%) 203 (18%) 160 (14%) 87 (8%) 36 (3%) <0.0001
Other diagnoses 744 (67%) 624 (56%) 584 (52%) 541 (49%) 466 (42%) <0.0001
CKD-EPI eGFR (mL/min/1.73m2)
Mean (SD) 31.7 (13.4) 26.6 (12.3) 23.7 (11.9) 22.6 (11.6) 20.9 (12.0) <0.0001
60 34 (3%) 16 (1%) 7 (1%) 5 (0%) 12 (1%) <0.0001
30 to<60 540 (49%) 373 (34%) 300 (27%) 267 (24%) 221 (20%) <0.0001
15 to<30 466 (42%) 534 (48%) 510 (46%) 502 (46%) 451 (41%) 0.0022
<15 69 (6%) 186 (17%) 303 (27%) 328 (30%) 428 (38%) <0.0001
Urinary ACR (mg/g) 11 (6–19) 63 (44–88) 208 (155–265) 601 (457–764) 1866 (1325–3002) <0.0001
eCER (mg/day)a 1329 (1007–1556) 1354 (1031–1578) 1370 (1038–1614) 1422 (1057–1630) 1416 (1057–1640) <0.0001
eAER (mg/day)a 14 (8–24) 80 (54–114) 265 (201–352) 781 (589–1057) 2513 (1819–3983) <0.0001
Data are n (%), mean (standard deviation) or median (interquartile range). ACR, albumin:creatinine ratio; eCER, estimated creatinine excretion rate; CKD-EPI, Chronic Kidney
Disease Epidemiology Collaboration; eAER, estimated albumin excretion rate; eGFR, estimated glomerular ﬁltration rate.
aCalculated using the Ellam equation for estimated creatinine excretion rate.
FIGURE 2: Relative risk of ESRD at different levels of ACR and eAER. ACR, albumin:creatinine ratio; eAER, estimated albumin excretion rate;
ESRD, end-stage renal disease; SD, standard deviation. The relative risks (adjusted for age, sex and eGFR) and 95% conﬁdence intervals are
plotted against the mean usual value (i.e. the medium-term average value). Participants are split into ﬁve equally sized groups with the top ﬁfth
further divided equally in two.
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|prognostic information for ESRD risk over and above each
other when accounting for the competing risk of death before
ESRD (Supplementary Table S3).
Measures of albuminuria and the risk of VEs
During follow-up 1204 participants suffered a fatal or non-
fatal VE. Baseline urine ACR and eAEREllam had modest posi-
tive associations with the risk of VEs after adjustment for estab-
lished cardiovascular risk factors and eGFR (Figure 3), with
almost identical RRs: RR per 10-fold higher ACR 1.37 (95% CI
1.22–1.53); and per 10-fold higher eAER 1.36 (1.22–1.52)
(Table 2). Again, neither ACR or eAER provided any additional
prognostic information for VE risk over and above each other
[improvement in risk prediction for eAER over and above ACR
(v21 ¼ 0.8); for ACR over and above eAER (v21¼ 0.5);
Supplementary Table S4].
Findings were similar when eAER was calculated using the
formulae that included weight (Supplementary Table S4)
[10, 11].
Measures of albuminuria and mortality
In total, 1130 participants died during follow-up, 369 from a
vascular cause and 641 from a non-vascular cause. The cause of
death was not known in 120 participants. After adjustment for
established risk factors and eGFR, both ACR and eAEREllam
showed modest associations with both vascular and non-vascular
mortality, and consequently all-cause mortality (Figure 4). After
adjustment for known cardiovascular risk factors and eGFR, a
10-fold higher ACR or eAEREllam was associated with almost
identical RRs for vascular mortality [1.64 (1.33–2.03) and 1.63
(1.32–2.00), respectively], for non-vascular mortality [1.52 (1.30–
1.78) and 1.50 (1.29–1.76), respectively] and hence for all-cause
mortality [1.56 (1.38–1.75) and 1.54 (1.37–1.73), respectively]
(Table 2).
For vascular mortality, neither measure significantly improved
model fit over and above the other (v21 ¼ 2.0 for eAER over and
above ACR and v21¼ 2.3 for ACR over and above eAER;
Supplementary Table S5). For non-vascular mortality, however,
knowledge of both albuminuria measures resulted in small, but
significant, improvements in risk prediction compared with
knowledge of either one in isolation v21¼ 8.2 for eAER over and
above ACR and v21¼ 9.1 for ACR over and above eAER;
Supplementary Table S5). Again, findings were similar when
alternative equations that included weight [10, 11] were used to
estimate eAER (Supplementary Table S5).
DISCUSSION
Albuminuria is recognized as a strong predictor of the risk of
ESRD and of VEs [2, 4]. This report confirms these associations
but shows that eAER (a more accurate estimate of 24-h urine
albumin excretion than ACR) does not provide more prognos-
tic information than ACR in terms of ESRD or vascular risk.
The likely explanation for this finding lies in relationships
between ACR and eAER and measured albuminuria.
Table 2. Age- and sex-adjusted relevance of each marker of albuminuria to
ESRD, vascular events and mortality risk before and after additional
adjustment for eGFR
Albuminuria marker Relative risk per 10-fold increase
in marker of albuminuria (95% CI)
Adjusted for
age and sex
Adjusted for age,
sex and eGFR
ESRD
ACR 3.52 (3.22, 3.85) 2.70 (2.45, 2.98)
eAEREllam 3.46 (3.17, 3.78) 2.67 (2.43, 2.94)
Vascular events
ACR 1.53 (1.38, 1.70) 1.37 (1.22, 1.53)
eAEREllam 1.53 (1.38, 1.69) 1.36 (1.22, 1.52)
Vascular mortality
ACR 1.97 (1.63, 2.40) 1.64 (1.33, 2.03)
eAEREllam 1.95 (1.61, 2.36) 1.63 (1.32, 2.00)
Non-vascular mortality
ACR 1.88 (1.63, 2.18) 1.52 (1.30, 1.78)
eAEREllam 1.86 (1.61, 2.15) 1.50 (1.29, 1.76)
All-cause mortality
ACR 1.88 (1.69, 2.10) 1.56 (1.38, 1.75)
eAEREllam 1.86 (1.67, 2.07) 1.54 (1.37, 1.73)
ACR, albumin:creatinine ratio; eAER, estimated albumin excretion rate; eGFR, estimated
glomerular ﬁltration rate; ESRD, end-stage renal disease; CI, conﬁdence interval.
FIGURE 3: Relative risk of vascular events at different levels of ACR and eAER. ACR, albumin:creatinine ratio; eAER, estimated albumin excre-
tion rate; VE, vascular events; SD, standard deviation. The relative risks (adjusted for established risk factors and eGFR) and 95% conﬁdence
intervals are plotted against the mean usual value (i.e. the medium-term average value). The established risk factors included are: age, sex, eth-
nicity, country, systolic blood pressure, diastolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, smok-
ing status, prior diabetes and prior vascular disease.
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|The eAEREllam formula was derived from measurements of
24-h urinary excretion of albumin and creatinine in the MDRD
study [9]. One of the key findings from the derivation of this for-
mula was that almost all of the MDRD participants, with the
exception of White women, excreted substantially more than 1 g
of creatinine per day. Thus, estimates of 24-h albuminuria based
on ACR, which assumes the amount of albumin per gram of crea-
tinine to be equivalent to the 24-h albumin excretion, are likely to
systematically underestimate measured albuminuria in most indi-
viduals. This is consistent with the authors’ finding that ACR
underestimated albuminuria in both validation cohorts, whereas
eAER produced a relatively unbiased estimate (assessed by the
median difference between ACR or eAER and measured 24-h
albuminuria) [9]. However, in the validation cohorts, eAER was
not more precise than ACR, meaning that, after accounting for
the bias, for any individual in the study the difference between the
ACR or eAER estimate and measured 24-h albuminuria was sim-
ilar (assessed by the interquartile range of the differences between
ACR or eAER and measured albuminuria). Because accuracy
(assessed as the proportion of individuals in whomACR or eAER
was within 30% or 50% of the measured albuminuria) is heavily
dependent on the bias, eAER is substantially more accurate in
predicting 24-h albuminuria than ACR [9]. In predicting events
in a prospective study, however, the bias is less important than
discrimination (i.e. the measure’s ability to order individuals
according to their level of risk).
Since eAER aims to account for differences in creatinine
excretion between individuals it might be expected to perform
better than ACR in predicting ESRD without adjustment for
other factors, including age and sex. However, in this study,
eAER did not provide any additional prognostic information
over ACR in predicting ESRD risk in either the null or the
adjusted model. Furthermore, knowledge of eAER and ACR
was no more informative than ACR alone in predicting ESRD
in subgroups expected to have lower creatinine excretion (e.g.
women, those aged over 70 years, Asian participants, those
weighing under 70 kg) or higher creatinine excretion (e.g. men,
those aged under 50 years, White participants and those weigh-
ing over 85 kg). It is also interesting that the formulae that
included weight in the calculation of CER (eAERIx or
eAERWalser), and therefore eAER, also did not provide addi-
tional prognostic information over ACR. However, similar to
the eAEREllam equation, in the Prevention of Renal and
Vascular Endstage Disease (PREVEND) cohort neither the
eAERIx or the eAERWalser formulae were more precise than
ACR in predicting measured albuminuria, although they both
produced a less biased estimate of albuminuria than ACR [10].
This current study has several important strengths. First, the
large number of ESRD events mean that we were able to not
only estimate the risks associated with higher albuminuria very
precisely, but also compare the predictive performance of meas-
ures of albuminuria separately in a number of important
FIGURE 4: Relative risk of mortality at different levels of ACR and eAEREllam, after adjustment for established risk factors and estimated glo-
merular ﬁltration rate. ACR, albumin:creatinine ratio; eAER, estimated albumin excretion rate; SD, standard deviation. The relative risks and
95% conﬁdence intervals are plotted against the mean usual value (i.e. the medium-term average value). The established risk factors included
are: age, sex, ethnicity, country, systolic blood pressure, diastolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein
cholesterol, smoking status, prior diabetes and prior vascular disease.
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|subgroups. Second, the measurement of urine and blood bio-
chemistries was conducted in a central laboratory using stand-
ard methods. Third, the study population had a wide range of
albuminuria including over 1000 individuals with an ACR
of>1 g/g.
A number of limitations require consideration. First, albumi-
nuria was measured using a sample collected at only a single
time-point. Within individuals, day-to-day variability of albu-
minuria is substantial [22] and the use of albuminuria measured
at just a single time point would underestimate the strength of
the true association between usual albuminuria and risk [16].
We were, to some extent, able to overcome this problem by cor-
recting for the regression dilution bias [16]. The regression dilu-
tion ratio (the correlation between baseline ACR or eAER and a
repeat measurement collected around 2.5 years later) was 0.75
for both albuminuria measures and therefore correction for this
within-individual variation resulted in an association between
usual ACR or eAER and risk of ESRD, VEs and mortality
(reported here) that was approximately one-third stronger than
would have been observed without correction [16]. Second,
measures of 24-h albuminuria were not available and so we
were not able to assess the prognostic ability of eAER compared
with a ‘gold standard’. However, the aim of these analyses was
to assess whether eAER is superior in terms of predicting ESRD
or VEs to ACR, the albuminuria measure used in clinical prac-
tice [6]. Third, the study included only individuals with moder-
ate to severe CKD and therefore it is possible that eAER might
be more useful that ACR in predicting ESRD or VEs in the gen-
eral population.
As a major use of ACR in clinical practice is to predict risk
of progression of CKD (and to a lesser extent, risk of vascular
disease), an important question is whether eAER provides
superior prognostic information to ACR alone. These analy-
ses show that if ACR is already known (as it would be in clini-
cal practice), eAER provides no extra predictive prognostic
information.
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